Aurora Kinases as Potential Therapeutic Targets for Tumors with pRB and/or MYCN Dysregulation

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Dysregulated RB1 tumor suppressor and MYC oncogenes drive many cancers.
• RB1 mutations are loss-of-function, and MYCN is pharmacologically challenging to target.
• Aurora kinases (AURKs), particularly AURKA and AURKB, are implicated in these cancers.

Purpose of the Study:

• To review the rationale and functional roles of targeting AURKs in cancer therapy.
• To assess the clinical status and adverse effects of AURKA-specific inhibitors.
• To introduce proteolysis targeting chimeras (PROTACs) as a novel therapeutic strategy.

Main Methods:

• Literature review of studies on RB1, MYCN, and AURKs.
• Analysis of clinical trial data for AURKA inhibitors.
• Exploration of PROTAC technology for targeted protein degradation.

Main Results:

• Targeting AURKs shows therapeutic potential in RB1/MYCN-driven cancers.
• AURKA inhibitors are in clinical evaluation, with known adverse effects.
• PROTACs offer a new method for selective AURK degradation.

Conclusions:

• AURKs are viable therapeutic targets in specific cancer types.
• AURKA inhibitors are progressing clinically, requiring careful management of side effects.
• PROTACs present a promising, innovative approach for targeted cancer therapy by degrading AURKs.